Table 2:
Pooled incidences of fibrosis progression and regression among randomized controlled trials
| Baseline fibrosis stage | No. of studies/patients | Person-years of follow up | Progression | Regression | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of cases | Incidence rate (cases/100 person-years) | No. of stages | Incidence rate (stages/100 person-years) | Time to progress by 1 stage (years) | No. of cases | Incidence rate (cases/100 person-years) | No. of stages | Incidence rate (stages/100 person-years) | Time to regress by 1 stage (years) | |||
| NAFLD | ||||||||||||
| F0 | 4/104 | 108.9 | 19 | 19.1 (9.4–39.1) | 22 | 23.4 (10.9–50.3) | 4.3 (2.0–9.2) | NA | NA | NA | NA | NA |
| F1 | 5/89 | 109.9 | 28 | 25.4 (13.4–48.1) | 37 | 34.0 (19.8–58.4) | 2.9 (1.7–5.1) | 14 | 12.7 (7.5–21.5) | 14 | 12.7 (7.5–21.5) | 7.9 (4.7–13.3) |
| F2 | 5/111 | 146.3 | 27 | 18.5 (12.7–26.9) | 30 | 20.3 (13.4–30.7) | 4.9 (3.3–7.5) | 31 | 21.2 (14.9–30.1) | 36 | 24.6 (17.8–34.1) | 4.1 (2.9–5.6) |
| F3 | 10/423 | 576.8 | 54 | 8.0 (4.5–14.0) | 54 | 8.0 (4.5–14.0) | 12.5 (7.1–22.2) | 94 | 17.2 (12.9–22.9) | 132 | 24.0 (17.4–33.0) | 4.2 (3.0–5.7) |
| F4 | 4/252 | 370.2 | NA | NA | NA | NA | NA | 34 | 9.0 (4.6–17.9) | 34 | 9.0 (4.6–17.9) | 11.1 (5.6–21.7) |
| NASH | ||||||||||||
| F0 | 3/29 | 33.9 | 10 | 29.4 (14.2–60.8) | 13 | 38.4 (22.3–66.1) | 2.6 (1.5–4.5) | NA | NA | NA | NA | NA |
| F1 | 5/89 | 109.9 | 28 | 25.4 (13.4–48.1) | 37 | 34.0 (19.8–58.4) | 2.9 (1.7–5.1) | 14 | 12.7 (7.5–21.5) | 14 | 12.7 (7.5–21.5) | 7.9 (4.7–13.3) |
| F2 | 4/94 | 129.3 | 27 | 20.9 (14.3–30.5) | 30 | 23.2 (16.2–33.2) | 4.3 (3.0–6.2) | 23 | 17.8 (11.8–26.8) | 28 | 21.7 (15.0–31.4) | 4.6 (3.2–6.7) |
| F3 | 9/415 | 568.8 | 54 | 8.4 (4.9–14.3) | 54 | 8.4 (4.9–14.3) | 11.9 (7.0–20.4) | 94 | 17.7 (13.2–23.6) | 132 | 25.0 (18.3–34.3) | 4.0 (2.9–5.5) |
| F4 | 4/252 | 370.2 | NA | NA | NA | NA | NA | 34 | 9.0 (4.6–17.9) | 34 | 9.0 (4.6–17.9) | 11.1 (5.6–21.7) |
Note: No meta-analysis was possible for patients with NAFL because no randomized controlled trials provided data separately for patients with versus without NASH. NAFLD, Non-alcoholic Fatty Liver Disease; NAFL, Non-alcoholic Fatty Liver; NASH, Non-alcoholic Steatohepatitis.